Prothena (PRTA) Expected to Post Earnings on Monday

Prothena (NASDAQ:PRTA) is projected to announce its Q2 2026 results after the market closes on Monday, August 3rd. Analysts expect Prothena to post earnings of ($0.39) per share and revenue of $0.4220 million for the quarter. Interested persons can check the company’s upcoming Q2 2026 earning summary page for the latest details on the call scheduled for Thursday, August 6, 2026 at 4:00 PM ET.

Prothena (NASDAQ:PRTA) last announced its earnings results on Thursday, May 7th. The biotechnology company reported $0.60 earnings per share for the quarter, beating the consensus estimate of ($0.31) by $0.91. The firm had revenue of $51.08 million during the quarter, compared to the consensus estimate of $0.81 million. Prothena had a negative net margin of 260.92% and a negative return on equity of 43.44%. On average, analysts expect Prothena to post $0 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Prothena Stock Performance

NASDAQ:PRTA opened at $8.75 on Monday. The firm has a market cap of $458.06 million, a price-to-earnings ratio of -3.10, a price-to-earnings-growth ratio of 1.40 and a beta of -0.31. The company’s 50-day moving average is $9.15 and its two-hundred day moving average is $9.45. Prothena has a 12-month low of $6.58 and a 12-month high of $11.80.

Insider Buying and Selling

In other Prothena news, major shareholder William P. Scully purchased 20,000 shares of the stock in a transaction on Tuesday, June 16th. The stock was bought at an average price of $7.90 per share, for a total transaction of $158,000.00. Following the acquisition, the insider directly owned 756,000 shares of the company’s stock, valued at $5,972,400. This represents a 2.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is available at this link. In the last three months, insiders bought 345,000 shares of company stock valued at $3,097,250. 10.40% of the stock is owned by insiders.

Institutional Investors Weigh In On Prothena

Several hedge funds have recently modified their holdings of the stock. Jacobs Levy Equity Management Inc. purchased a new stake in Prothena in the first quarter valued at approximately $230,000. Polymer Capital Management US LLC purchased a new position in Prothena during the fourth quarter worth approximately $225,000. Headlands Technologies LLC purchased a new position in Prothena during the fourth quarter worth approximately $223,000. Raymond James Financial Inc. boosted its holdings in shares of Prothena by 63.2% in the 3rd quarter. Raymond James Financial Inc. now owns 22,032 shares of the biotechnology company’s stock valued at $215,000 after purchasing an additional 8,536 shares during the last quarter. Finally, Intech Investment Management LLC boosted its holdings in shares of Prothena by 6.3% in the 4th quarter. Intech Investment Management LLC now owns 20,601 shares of the biotechnology company’s stock valued at $197,000 after purchasing an additional 1,213 shares during the last quarter. 97.08% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of equities research analysts have recently commented on PRTA shares. HC Wainwright reiterated a “buy” rating and set a $30.00 price target on shares of Prothena in a report on Friday. Wall Street Zen lowered shares of Prothena from a “buy” rating to a “hold” rating in a research report on Saturday. Citigroup restated an “outperform” rating on shares of Prothena in a research report on Friday, May 8th. UBS Group reaffirmed a “buy” rating on shares of Prothena in a research note on Friday. Finally, Citizens Jmp boosted their price target on Prothena from $19.00 to $20.00 and gave the company a “market outperform” rating in a report on Friday, May 8th. One analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $23.75.

About Prothena

Prothena Corporation plc is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for neurodegenerative and rare diseases driven by misfolded proteins. The company’s research focuses on immunotherapies and small molecules designed to target and clear disease-causing protein aggregates. Prothena leverages proprietary protein engineering and antibody discovery platforms to advance candidates through preclinical and clinical stages.

The company’s most advanced program is an antibody targeting aggregated alpha-synuclein for the potential treatment of Parkinson’s disease, currently in mid-stage clinical trials.